How ASX shares vs. property performed in December

The median Australian home value fell for the first time in almost two years last month.

Happy woman holding white house model in hand and pointing to it with a pen.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There was a reversal of trends between ASX shares vs. property last month, with bricks-and-mortar investments delivering a stronger performance than stocks.

But neither asset class finished the month in the green. In fact, the median national dwelling value fell for the first time in almost two years, according to CoreLogic data.

The S&P/ASX 200 Index (ASX: XJO) started the month well, hitting a new all-time record high of 8,514.5 points on 3 December. But then it tumbled, losing 3.28% in value by the closing bell on 31 December.

Last month's weak performance followed a strong 3.38% gain in November for ASX 200 shares.

Meantime, the median national home value fell by 0.1% as buyer demand weakened amid higher supply.

CoreLogic said the first decline in 23 months marked the end of a surprisingly strong and resilient period of growth despite high interest rates, cost-of-living pressures, and reduced borrowing capacity.

Shares vs. property: What happened in the final month of 2024?

The mid-sized cities of Perth, Adelaide, and Brisbane continued their value ascension but at a slower pace.

Perth, Adelaide, and Brisbane recorded median home price gains of 0.7%, 0.6%, and 0.5%, respectively.

Home values fell by (0.6%) in Sydney, (0.7%) in Melbourne, and (0.5%) in both Hobart and Canberra.

Tim Lawless, CoreLogic's research director, said:

This result represents the housing market catching up with the reality of market dynamics.

Growth in housing values has been consistently weakening through the second half of the year, as affordability constraints weighed on buyer demand and advertised supply levels trended higher.

Let's review the numbers.

Shares vs. property: Here are the numbers for December

Property marketMedian house pricePrice change last month12-month price change
Sydney$1,470,625(0.7%)2.5%
Melbourne$917,616(0.8%)(2.9%)
Brisbane$977,5750.4%10.2%
Adelaide$866,3270.6%12.5%
Perth$847,5180.6%18.7%
Hobart $693,924(0.4%)(0.5%)
Darwin $586,6990.5%1.4%
Canberra$965,910(0.6%)0.4%
Regional New South Wales$775,3780.0%3.2%
Regional Victoria$600,504(0.3%)(2.7%)
Regional Queensland$705,3660.5%10.8%
Regional South Australia$463,7541.3%12.6%
Regional Western Australia$570,8390.9%16%
Regional Tasmania$545,0900.5%3.4%
Regional Northern Territory$421,6011.5%(2.5%)
Source: CoreLogic

Top 5 risers of the ASX 200 last month

Here are the five best-performing ASX 200 shares of the month based on share price growth.

ASX 200 shareShare price growth
De Grey Mining Limited (ASX: DEG)16.12%
Beach Energy Ltd (ASX: BPT)13.41%
Insignia Financial Ltd (ASX: IFL)13.06%
Auckland International Airport Limited (ASX: AIA) 10.54%
Gold Road Resources Ltd (ASX: GOR)9.63%

Why did the De Grey Mining share price go 16% higher?

Last month, the ASX 200's biggest gold miner, Northern Star Resources Ltd (ASX: NST), lobbed a $5 billion takeover offer at De Grey Mining, which it accepted.

The companies have entered into a binding scheme implementation deed. This will see Northern Star acquire 100% of De Grey Mining shares via a court-approved scheme of arrangement.

De Grey Mining shareholders will receive 0.119 new Northern Star shares for each De Grey share held.

As my colleague James reported, the deal implied an offer price of $2.08 per share for De Grey Mining, which was a 36.8% premium at the time.

News of the deal sent De Grey Mining shares skyrocketing 29.61% to a 17-year high of $1.99 on the day of the announcement. De Grey Mining shares finished the month at $1.77 per share.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Growth Shares

These 4 ASX 200 stocks could jump another 70% to 80% in 2026

These stocks are expected to rocket higher.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Share Gainers

3 ASX 200 stocks jumping higher in this week's falling market

Investors shrugged off the broader market retrace and piled into these three ASX 200 stocks this week.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why EOS, Lotus Resources, REA, and Web Travel shares are dropping today

These shares are ending the week deep in the red. But why?

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Brambles, HMC Capital, ResMed, and Rio Tinto shares are rising today

These shares are avoiding the selloff and are pushing higher on Friday.

Read more »

A woman looks shocked as she drinks a coffee while reading the paper.
Share Fallers

Why is the Web Travel share price crashing 41% on Friday?

ASX investors are pummelling Web Travel shares today. But why?

Read more »

A man looking at his laptop and thinking.
Materials Shares

Rio Tinto shares charge higher after Glencore merger collapses

The parties couldn't come to an agreement.

Read more »

a group of doctors and medical staff in uniform high five in celebration in a hospital setting
Share Market News

Neuren Pharmaceuticals kicks off Phase 3 trial in rare syndrome

Neuren Pharmaceuticals shares are on watch after dosing began in its key Phase 3 trial for Phelan-McDermid syndrome.

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Broker Notes

Top broker forecasts another 83% upside for this outperforming ASX All Ords tech stock

A leading broker expects outsized gains from this ASX All Ords tech stock in 2026. But why?

Read more »